During my career, the treatment of Congestive Heart Failure (CHF) has improved dramatically, withe longevity the rule, rather than the exception, since the development of a multidrug regimen that includes: ACE Inhibitors/ARB’s, Beta Blockers, Aldosterone Inhibitors, and Diuretics.
A new addition, Entresto, appears to provide further improvement in CHF, enough to warrant some tempered excitement among cardiologists. Milton Packer, MD….a icon in research on Heart Failure, speaks to this excitement >>>HERE<<<
The medication is expensive ($4500/year), but if it’s advantages prove themselves in the real world, this will be another major step forward in managing CHF patients.
Read the original study >>>>HERE<<<<